FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3127702912> ?p ?o ?g. }

• W3127702912 endingPage "1000" @default.
• W3127702912 startingPage "990" @default.
• W3127702912 abstract "Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastases. A phase I and Ib study of modified oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) with ADX revealed encouraging antitumor activity in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma.This phase III, randomized, double-blinded, placebo (PBO)-controlled multicenter study investigated the efficacy and safety of mFOLFOX6 with and without ADX in patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma. Random assignment was 1:1 to mFOLFOX6 + ADX or mFOLFOX6 + PBO. ADX/PBO 800 mg was infused on days 1 and 15 of each 28-day cycle. Protocol therapy was given until disease progression or intolerance. The primary end point was overall survival (OS), and secondary end points were progression-free survival (PFS), objective response rate (RECIST 1.1), and safety.Between September 2015 and May 2017, 432 patients were randomly assigned, 218 to ADX and 214 to PBO. The median OS was 12.5 versus 11.8 months in the ADX and PBO groups, respectively. The median PFS was 7.5 versus 7.1 months in the ADX and PBO groups, respectively. The objective response rate was 51% in the ADX group and 41% in the PBO group. Among the subgroup analyses, patients of age ≥ 65 years had an improved OS and PFS with ADX versus PBO; the P values and CIs were not adjusted for multiplicity. There were no meaningful differences in the safety profile of the ADX versus PBO groups.The addition of ADX to mFOLFOX6 did not improve OS in unselected patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma." @default.
• W3127702912 created "2021-02-15" @default.
• W3127702912 creator A5012142507 @default.
• W3127702912 creator A5019473289 @default.
• W3127702912 creator A5021710351 @default.
• W3127702912 creator A5028472820 @default.
• W3127702912 creator A5033985179 @default.
• W3127702912 creator A5042529049 @default.
• W3127702912 creator A5044064524 @default.
• W3127702912 creator A5044392059 @default.
• W3127702912 creator A5056345420 @default.
• W3127702912 creator A5066052401 @default.
• W3127702912 creator A5089202777 @default.
• W3127702912 date "2021-03-20" @default.
• W3127702912 modified "2023-10-16" @default.
• W3127702912 title "Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)" @default.
• W3127702912 cites W1428077152 @default.
• W3127702912 cites W16797474 @default.
• W3127702912 cites W1988556605 @default.
• W3127702912 cites W2002125536 @default.
• W3127702912 cites W2005334224 @default.
• W3127702912 cites W2008164090 @default.
• W3127702912 cites W2016650805 @default.
• W3127702912 cites W2016859011 @default.
• W3127702912 cites W2019607817 @default.
• W3127702912 cites W2020947105 @default.
• W3127702912 cites W2077995672 @default.
• W3127702912 cites W2080860848 @default.
• W3127702912 cites W2104631255 @default.
• W3127702912 cites W2114734455 @default.
• W3127702912 cites W2119293400 @default.
• W3127702912 cites W2125201819 @default.
• W3127702912 cites W2132871418 @default.
• W3127702912 cites W2152728784 @default.
• W3127702912 cites W2154401382 @default.
• W3127702912 cites W2168428587 @default.
• W3127702912 cites W2263045610 @default.
• W3127702912 cites W2305101902 @default.
• W3127702912 cites W2335839753 @default.
• W3127702912 cites W2566893583 @default.
• W3127702912 cites W2591053562 @default.
• W3127702912 cites W2610632374 @default.
• W3127702912 cites W2613448640 @default.
• W3127702912 cites W2620590125 @default.
• W3127702912 cites W2753479285 @default.
• W3127702912 cites W2777911228 @default.
• W3127702912 cites W2801869430 @default.
• W3127702912 cites W2803396075 @default.
• W3127702912 cites W2887352196 @default.
• W3127702912 cites W2897154408 @default.
• W3127702912 cites W2925979405 @default.
• W3127702912 cites W2969047211 @default.
• W3127702912 cites W3004948796 @default.
• W3127702912 doi "https://doi.org/10.1200/jco.20.02755" @default.
• W3127702912 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8078292" @default.
• W3127702912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33577358" @default.
• W3127702912 hasPublicationYear "2021" @default.
• W3127702912 type Work @default.
• W3127702912 sameAs 3127702912 @default.
• W3127702912 citedByCount "22" @default.
• W3127702912 countsByYear W31277029122021 @default.
• W3127702912 countsByYear W31277029122022 @default.
• W3127702912 countsByYear W31277029122023 @default.
• W3127702912 crossrefType "journal-article" @default.
• W3127702912 hasAuthorship W3127702912A5012142507 @default.
• W3127702912 hasAuthorship W3127702912A5019473289 @default.
• W3127702912 hasAuthorship W3127702912A5021710351 @default.
• W3127702912 hasAuthorship W3127702912A5028472820 @default.
• W3127702912 hasAuthorship W3127702912A5033985179 @default.
• W3127702912 hasAuthorship W3127702912A5042529049 @default.
• W3127702912 hasAuthorship W3127702912A5044064524 @default.
• W3127702912 hasAuthorship W3127702912A5044392059 @default.
• W3127702912 hasAuthorship W3127702912A5056345420 @default.
• W3127702912 hasAuthorship W3127702912A5066052401 @default.
• W3127702912 hasAuthorship W3127702912A5089202777 @default.
• W3127702912 hasBestOaLocation W31277029121 @default.
• W3127702912 hasConcept C121608353 @default.
• W3127702912 hasConcept C126322002 @default.
• W3127702912 hasConcept C126894567 @default.
• W3127702912 hasConcept C141071460 @default.
• W3127702912 hasConcept C143998085 @default.
• W3127702912 hasConcept C168563851 @default.
• W3127702912 hasConcept C203092338 @default.
• W3127702912 hasConcept C2776694085 @default.
• W3127702912 hasConcept C2780962732 @default.
• W3127702912 hasConcept C2781182431 @default.
• W3127702912 hasConcept C31760486 @default.
• W3127702912 hasConcept C526805850 @default.
• W3127702912 hasConcept C71924100 @default.
• W3127702912 hasConcept C90924648 @default.
• W3127702912 hasConceptScore W3127702912C121608353 @default.
• W3127702912 hasConceptScore W3127702912C126322002 @default.
• W3127702912 hasConceptScore W3127702912C126894567 @default.
• W3127702912 hasConceptScore W3127702912C141071460 @default.
• W3127702912 hasConceptScore W3127702912C143998085 @default.
• W3127702912 hasConceptScore W3127702912C168563851 @default.
• W3127702912 hasConceptScore W3127702912C203092338 @default.
• W3127702912 hasConceptScore W3127702912C2776694085 @default.

• next